Published in Blood on April 23, 2012
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12
Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials (2014) 1.62
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood (2014) 1.59
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia (2014) 1.43
Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood (2013) 1.21
SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol (2014) 1.12
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
Association of response endpoints with survival outcomes in multiple myeloma. Leukemia (2013) 1.08
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia (2013) 1.05
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov (2015) 1.01
Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J (2013) 1.01
A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit. Front Immunol (2013) 0.99
TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood (2014) 0.97
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife (2014) 0.95
Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One (2013) 0.95
canEvolve: a web portal for integrative oncogenomics. PLoS One (2013) 0.95
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun (2015) 0.95
Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle (2015) 0.94
Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J (2013) 0.94
Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol (2014) 0.94
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia (2014) 0.92
A one-page summary report of genome sequencing for the healthy adult. Public Health Genomics (2015) 0.92
Genetics of multiple myeloma: another heterogeneity level? Blood (2015) 0.91
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia (2014) 0.89
Darwinian evolution and tiding clones in multiple myeloma. Blood (2012) 0.89
How I treat smoldering multiple myeloma. Blood (2014) 0.89
Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomark Res (2013) 0.89
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer (2013) 0.88
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant (2013) 0.88
Differential and limited expression of mutant alleles in multiple myeloma. Blood (2014) 0.87
Serial exome analysis of disease progression in premalignant gammopathies. Leukemia (2014) 0.87
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol (2015) 0.87
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget (2015) 0.85
Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proc Natl Acad Sci U S A (2015) 0.85
Molecular pathogenesis of multiple myeloma. Int J Clin Oncol (2015) 0.83
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. Leukemia (2015) 0.83
Implications of heterogeneity in multiple myeloma. Biomed Res Int (2014) 0.82
The translocation t(4;14) can be present only in minor subclones in multiple myeloma. Clin Cancer Res (2013) 0.82
Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma. PLoS One (2013) 0.82
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant (2013) 0.81
Pursuing the curative blueprint for early myeloma. Blood (2013) 0.81
Personalization of cancer treatment using predictive simulation. J Transl Med (2015) 0.81
ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. Oncotarget (2016) 0.81
Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud (2016) 0.80
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica (2014) 0.80
The Tao of myeloma. Blood (2014) 0.80
Multiple myeloma: so much progress, but so many unsolved questions. Haematologica (2013) 0.80
Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Curr Cancer Ther Rev (2015) 0.80
Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant (2016) 0.80
Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy. Cancer Res (2014) 0.80
Leukaemia 'firsts' in cancer research and treatment. Nat Rev Cancer (2016) 0.79
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res (2014) 0.78
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 0.78
Aggressive FLC Escape in a Patient with IgD Myeloma. Case Rep Hematol (2015) 0.77
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer J (2015) 0.77
Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells. Exp Hematol (2015) 0.77
The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res (2014) 0.77
Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma. Oncotarget (2015) 0.77
TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells. Blood Cancer J (2014) 0.76
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J (2016) 0.76
Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol (2017) 0.75
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. Biomed Res Int (2015) 0.75
Genome-scale technology driven advances to research into normal and malignant haematopoiesis. Scientifica (Cairo) (2012) 0.75
Consolidation in multiple myeloma - current status and perspectives. Contemp Oncol (Pozn) (2014) 0.75
Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. J Autoimmun (2013) 0.75
Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib. PLoS One (2015) 0.75
Identification of the key genes connected with plasma cells of multiple myeloma using expression profiles. Onco Targets Ther (2015) 0.75
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica (2014) 0.75
Long-term survival in multiple myeloma. Clin Case Rep (2014) 0.75
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget (2016) 0.75
The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs (2015) 0.75
Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. Oncotarget (2016) 0.75
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget (2016) 0.75
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc (2017) 0.75
Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncol Lett (2017) 0.75
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia (2016) 0.75
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia (2017) 0.75
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 38.62
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods (2010) 16.61
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 3.93
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 3.69
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell (2010) 3.47
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet (2006) 3.39
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood (1996) 2.21
Hypodiploidy is a major prognostic factor in multiple myeloma. Blood (2001) 2.17
Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res (2005) 1.56
Plasma cell leukemia: an evaluation of response to therapy. Am J Med (1987) 1.51
A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood (1995) 1.48
Genomics in multiple myeloma. Clin Cancer Res (2011) 1.34
The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia (2010) 1.25
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia (1994) 1.16
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood (2001) 1.15
Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol (2009) 1.01
Deletion of the retinoblastoma gene in multiple myeloma. Leukemia (1994) 0.99
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am J Hematol (2009) 0.98
Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene (2010) 0.93
High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol (1995) 0.92
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. Proc Natl Acad Sci U S A (2004) 7.70
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet (2010) 3.91
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J Clin Invest (2005) 3.56
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med (2007) 3.33
Common Kibra alleles are associated with human memory performance. Science (2006) 3.30
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract (2012) 3.27
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature (2011) 3.10
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med (2003) 3.07
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet (2009) 2.73
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med (2005) 2.67
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45